Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRK NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$113.01-1.1%$115.90$75.40▼$125.14$279.12B0.1810.90 million shs9.13 million shsTRVITrevi Therapeutics$13.88+4.8%$13.06$5.38▼$16.12$1.88B1.071.50 million shs1.26 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+1.42%+1.63%-4.00%-6.19%+48.05%TRVITrevi Therapeutics-1.41%-10.30%-13.07%+29.93%+104.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$113.01-1.1%$115.90$75.40▼$125.14$279.12B0.1810.90 million shs9.13 million shsTRVITrevi Therapeutics$13.88+4.8%$13.06$5.38▼$16.12$1.88B1.071.50 million shs1.26 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+1.42%+1.63%-4.00%-6.19%+48.05%TRVITrevi Therapeutics-1.41%-10.30%-13.07%+29.93%+104.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.68Moderate Buy$128.1813.42% UpsideTRVITrevi Therapeutics 3.00Buy$22.9064.99% UpsideCurrent Analyst Ratings BreakdownLatest MRK and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026TRVITrevi Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/6/2026TRVITrevi Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $23.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/20/2026TRVITrevi Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026TRVITrevi Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$65.77B4.24$11.47 per share9.85$18.60 per share6.08TRVITrevi TherapeuticsN/AN/AN/AN/A$1.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$18.25B$3.5531.8311.562.5313.59%27.55%10.73%8/4/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest MRK and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.403.01%+5.75%95.77%14 YearsTRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.1.021.301.06TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.17%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableMRK and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from BrokeragesMay 17 at 4:43 AM | americanbankingnews.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - SlideshowMay 15, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comNan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comF m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comComerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comTrevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030May 9, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenMay 9, 2026 | marketbeat.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comEquities Analysts Offer Predictions for TRVI Q2 EarningsMay 8, 2026 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day TranscriptMay 7, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comResearch Analysts Set Expectations for TRVI FY2030 EarningsMay 7, 2026 | marketbeat.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLCMay 6, 2026 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)May 6, 2026 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPSMay 5, 2026 | marketbeat.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comPictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVIMay 2, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and TRVI Company DescriptionsMerck & Co., Inc. NYSE:MRK$113.01 -1.23 (-1.07%) Closing price 03:59 PM EasternExtended Trading$113.12 +0.10 (+0.09%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Trevi Therapeutics NASDAQ:TRVI$13.88 +0.64 (+4.83%) Closing price 04:00 PM EasternExtended Trading$13.51 -0.37 (-2.69%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
